PL2968650T3 - Preparaty do oczu do dostarczania leku do tylnego fragmentu oka - Google Patents
Preparaty do oczu do dostarczania leku do tylnego fragmentu okaInfo
- Publication number
- PL2968650T3 PL2968650T3 PL14724204T PL14724204T PL2968650T3 PL 2968650 T3 PL2968650 T3 PL 2968650T3 PL 14724204 T PL14724204 T PL 14724204T PL 14724204 T PL14724204 T PL 14724204T PL 2968650 T3 PL2968650 T3 PL 2968650T3
- Authority
- PL
- Poland
- Prior art keywords
- eye
- drug
- delivery
- posterior segment
- ocular formulations
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784681P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027589 WO2014152661A1 (en) | 2013-03-14 | 2014-03-14 | Ocular formulations for drug-delivery to the posterior segment of the eye |
| EP14724204.4A EP2968650B1 (en) | 2013-03-14 | 2014-03-14 | Ocular formulations for drug-delivery to the posterior segment of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2968650T3 true PL2968650T3 (pl) | 2019-05-31 |
Family
ID=50625096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14724204T PL2968650T3 (pl) | 2013-03-14 | 2014-03-14 | Preparaty do oczu do dostarczania leku do tylnego fragmentu oka |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10092549B2 (pl) |
| EP (2) | EP2968650B1 (pl) |
| JP (3) | JP6542193B2 (pl) |
| KR (2) | KR102433489B1 (pl) |
| CN (2) | CN105142686B (pl) |
| AU (3) | AU2014239252B2 (pl) |
| BR (1) | BR112015021334B1 (pl) |
| CA (1) | CA2900840C (pl) |
| DK (1) | DK2968650T3 (pl) |
| ES (1) | ES2710152T3 (pl) |
| HU (1) | HUE042528T2 (pl) |
| IL (2) | IL240510B (pl) |
| MX (2) | MX360888B (pl) |
| PH (2) | PH12015501938B1 (pl) |
| PL (1) | PL2968650T3 (pl) |
| PT (1) | PT2968650T (pl) |
| RU (2) | RU2768489C2 (pl) |
| SA (1) | SA516380321B1 (pl) |
| SG (2) | SG11201507316UA (pl) |
| TR (1) | TR201901462T4 (pl) |
| WO (1) | WO2014152661A1 (pl) |
| ZA (2) | ZA201505447B (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679699B (zh) | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| AU2013314303B2 (en) | 2012-09-12 | 2018-01-18 | Novaliq Gmbh | Semifluorinated alkane compositions |
| RU2768652C1 (ru) * | 2014-09-17 | 2022-03-24 | Паноптика, Инк. | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза |
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| DK3426859T3 (da) | 2016-03-11 | 2021-09-13 | Georgia Pacific Gypsum Llc | Gipspanel, anvendelse af et sådant panel og fremgangsmåde til fremstilling af et sådant panel |
| CA3058097C (en) * | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| RU2652342C1 (ru) * | 2017-07-13 | 2018-04-25 | Наталья Александровна Гаврилова | Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| AT522609B1 (de) | 2019-05-28 | 2022-06-15 | Miba Frictec Gmbh | Reibvorrichtung |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
| MX2022003027A (es) * | 2019-09-13 | 2022-06-14 | The Us Secretary Department Of Health & Human Services | Diana susceptible a modularse por farmacos para tratar degeneracion retiniana. |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
| EP4644390A4 (en) * | 2022-12-28 | 2026-04-15 | Beyang Therapeutics Co Ltd | Protein Tyrosine Kinase Inhibitor and its Medical Uses |
| WO2025058571A1 (en) * | 2023-09-15 | 2025-03-20 | Agency For Science, Technology And Research | Polymer composition comprising a thermogelling polymer and a tyrosine kinase inhibitor, and related methods thereof |
| WO2026002126A1 (zh) * | 2024-06-27 | 2026-01-02 | 苏州必扬医药科技有限公司 | 一种蛋白酪氨酸激酶抑制剂及其眼用制剂 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891913A (en) | 1994-10-10 | 1999-04-06 | Novartis Finance Corporation | Ophthalmic and aural compositions containing diclofenac potassium |
| JPH10203960A (ja) | 1997-01-24 | 1998-08-04 | Ofutekusu:Kk | 点眼液組成物 |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| JP4682495B2 (ja) * | 1999-09-06 | 2011-05-11 | 小野薬品工業株式会社 | 眼疾患の予防、治療剤 |
| IL155371A0 (en) * | 2000-11-28 | 2003-11-23 | Pfizer Prod Inc | Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
| EP1527071A1 (en) | 2002-07-25 | 2005-05-04 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
| WO2004023397A1 (ja) * | 2002-08-29 | 2004-03-18 | Kistem Co., Ltd | 視覚補助ネットワークサーバ、視覚補助ネットワークシステム、視覚補助方法、視覚補助システム、色覚機能通知システム、色覚機能通知用プログラム、色覚機能通知方法、色覚補助システム、色覚補助用プログラム、及び色覚補助方法 |
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
| US7483533B2 (en) * | 2004-08-05 | 2009-01-27 | King Fahd University Of Petroleum | Elliptic polynomial cryptography with multi x-coordinates embedding |
| JP2006111621A (ja) * | 2004-09-15 | 2006-04-27 | Santen Pharmaceut Co Ltd | ピレノキシン懸濁型点眼剤 |
| AU2005304035B2 (en) * | 2004-11-09 | 2010-07-22 | Santen Sas | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| AU2006254825A1 (en) * | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| JP2007011785A (ja) * | 2005-06-30 | 2007-01-18 | Toshiba Corp | 情報処理装置、およびタッチパネルの振動制御方法 |
| JP2007012937A (ja) * | 2005-06-30 | 2007-01-18 | Seiko Epson Corp | 表示ドライバ |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| PT1937212E (pt) * | 2005-10-10 | 2010-11-30 | Novagali Pharma Sa | Emulsões oftálmicas contendo prostaglandinas |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| BRPI0807571A2 (pt) * | 2007-02-22 | 2014-07-01 | Othera Holding Inc | Compostos de hidroxilamina e métodos de seu uso |
| EP2179736A4 (en) * | 2007-08-09 | 2012-01-18 | Senju Pharma Co | TWO COMPONENT OPHTHALMIC DROPS CONTAINING PIRENOXIN |
| EP2310008A4 (en) * | 2008-07-09 | 2014-03-05 | Aspreva Internat Ltd | MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS |
| JP2010265261A (ja) * | 2009-04-17 | 2010-11-25 | Santen Pharmaceut Co Ltd | レボカバスチン懸濁型点眼剤 |
| JP2012250918A (ja) * | 2011-05-31 | 2012-12-20 | Rohto Pharmaceutical Co Ltd | ニューキノロン剤含有水性組成物 |
| WO2013126799A1 (en) | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
-
2014
- 2014-03-14 WO PCT/US2014/027589 patent/WO2014152661A1/en not_active Ceased
- 2014-03-14 RU RU2018128980A patent/RU2768489C2/ru active
- 2014-03-14 SG SG11201507316UA patent/SG11201507316UA/en unknown
- 2014-03-14 AU AU2014239252A patent/AU2014239252B2/en active Active
- 2014-03-14 HU HUE14724204A patent/HUE042528T2/hu unknown
- 2014-03-14 MX MX2015012653A patent/MX360888B/es active IP Right Grant
- 2014-03-14 EP EP14724204.4A patent/EP2968650B1/en active Active
- 2014-03-14 US US14/775,357 patent/US10092549B2/en active Active
- 2014-03-14 PL PL14724204T patent/PL2968650T3/pl unknown
- 2014-03-14 US US14/211,427 patent/US9446026B2/en active Active
- 2014-03-14 CN CN201480014617.7A patent/CN105142686B/zh active Active
- 2014-03-14 JP JP2016502486A patent/JP6542193B2/ja active Active
- 2014-03-14 KR KR1020157028846A patent/KR102433489B1/ko active Active
- 2014-03-14 CA CA2900840A patent/CA2900840C/en active Active
- 2014-03-14 RU RU2015143898A patent/RU2665953C2/ru active
- 2014-03-14 PT PT14724204T patent/PT2968650T/pt unknown
- 2014-03-14 KR KR1020217033904A patent/KR20210132205A/ko not_active Ceased
- 2014-03-14 TR TR2019/01462T patent/TR201901462T4/tr unknown
- 2014-03-14 MX MX2018014122A patent/MX386895B/es unknown
- 2014-03-14 CN CN202010184735.XA patent/CN111789814B/zh active Active
- 2014-03-14 SG SG10201710928PA patent/SG10201710928PA/en unknown
- 2014-03-14 ES ES14724204T patent/ES2710152T3/es active Active
- 2014-03-14 BR BR112015021334A patent/BR112015021334B1/pt active IP Right Grant
- 2014-03-14 EP EP18210412.5A patent/EP3520773A1/en active Pending
- 2014-03-14 DK DK14724204.4T patent/DK2968650T3/en active
-
2015
- 2015-07-29 ZA ZA2015/05447A patent/ZA201505447B/en unknown
- 2015-08-12 IL IL240510A patent/IL240510B/en active IP Right Grant
- 2015-09-02 PH PH12015501938A patent/PH12015501938B1/en unknown
- 2015-09-14 SA SA516380321A patent/SA516380321B1/ar unknown
-
2016
- 2016-08-19 US US15/241,545 patent/US20160354349A1/en not_active Abandoned
-
2017
- 2017-08-02 AU AU2017210543A patent/AU2017210543B2/en active Active
-
2018
- 2018-07-23 US US16/042,003 patent/US10307404B1/en active Active
-
2019
- 2019-04-16 US US16/385,711 patent/US20190240201A1/en not_active Abandoned
- 2019-04-23 US US16/391,425 patent/US20190247368A1/en not_active Abandoned
- 2019-04-24 AU AU2019202857A patent/AU2019202857B2/en active Active
- 2019-06-11 JP JP2019108399A patent/JP6965308B2/ja active Active
- 2019-08-15 PH PH12019501902A patent/PH12019501902A1/en unknown
- 2019-10-30 ZA ZA2019/07176A patent/ZA201907176B/en unknown
-
2020
- 2020-07-13 IL IL276016A patent/IL276016B/en unknown
-
2021
- 2021-03-12 US US17/199,506 patent/US20210196690A1/en not_active Abandoned
- 2021-10-20 JP JP2021171453A patent/JP2022009275A/ja active Pending
-
2024
- 2024-06-06 US US18/735,600 patent/US20240325357A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276016B (en) | Ocular formulations for administration of drug to the back of the eye | |
| IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| IL240931A0 (en) | History 3 - Phenylpropylamine is converted to the treatment of eye diseases and disorders | |
| IL282504A (en) | Ocular formulations for drug administration and protection of the front part of the eye | |
| IL244687A0 (en) | Epinephrine-based ophthalmic preparations for intraocular administration and methods for their production | |
| EP3061455A4 (en) | Therapeutic agent for ocular disease or prophylactic agent for ocular disease | |
| SG11201600813VA (en) | Method for producing anterior eye segment tissue | |
| SG11201508026RA (en) | Device providing enlargement & preventing collapse of the pupil of the eye | |
| SG11201506882YA (en) | Ophthalmic formulations | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| ZA201507718B (en) | The local treatment of inflammatory ophthalmic diseases | |
| GB2520410B (en) | Digital applanation tonometer | |
| GB2571647B (en) | The use of dipropylene/diethylene glycol dibenzoate to reduce eye irritation | |
| GB201303131D0 (en) | Ocular prosthesis | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| HK1227313A1 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| EP3170500A4 (en) | Prophylactic or therapeutic agent for diseases of posterior segment of eye |